Knight Therapeutics Inc KHTRF

Primary Symbol: T.GUD

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Revenue comparison 10 years later

<< Previous

Bullboard Posts

Next >>

Comment by EbbFlow88on Sep 23, 2022 8:18am

140 Views

Post# 34981175

RE:RE:Revenue comparison 10 years later

My thoughts exactly. They are certainly buying back here but the volume hasn't been very high so it seems buybacks are muted to save for a deal around the corner. Or they see a bigger market panic event to really put the buybacks to work.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China